2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvivalHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
2006
Update on the Management of Neuroendocrine Hepatic Metastases
Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the Management of Neuroendocrine Hepatic Metastases. Journal Of Vascular And Interventional Radiology 2006, 17: 1235-1250. PMID: 16923972, DOI: 10.1097/01.rvi.0000232177.57950.71.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBrachytherapyCatheter AblationChemoembolization, TherapeuticClinical Trials as TopicCryosurgeryEthanolHepatectomyHumansLiver NeoplasmsLiver TransplantationNeoplasms, Unknown PrimaryNeuroendocrine TumorsPractice Guidelines as TopicRadiology, InterventionalTomography, X-Ray ComputedTreatment OutcomeConceptsNeuroendocrine tumorsHepatic metastasesLong indolent courseYear of diagnosisMajority of patientsTime of diagnosisCare of patientsUnusual clinical presentationNeuroendocrine hepatic metastasesTumor growth patternMost patientsIndolent courseClinical presentationRespiratory tractPatientsOrgan systemsMetastasisDiagnosisImage-guided interventionsGrowth patternMalignancyTumorsTractCare